To assess whether inhibition of FUT8 in prostate cancer cells will be clinically useful, we next chose to investigate whether systemic treatment with SGN‐2FF (a cell permeable fucosyltransferase inhibitor which has shown promising effects on tumour cells, immune cells, and the tumour microenvironment [97, 98, 99, 100, 101, 102]) can inhibit the in vivo growth of prostate tumours in mice. Here, FUT8 is linked to prostate cancer.